Avtor/Urednik		Jovanović, Marija; Jančič, Eva; Janić, Miodrag; Janež, Andrej; Lunder, Mojca
Naslov		Semaglutid - prvi peroralni agonist receptorjev GLP-1 za zdravljenje sladkorne bolezni tipa 2
Prevedeni naslov		Semaglutide - the first oral GLP-1 receptor agonist for the treatment of type 2 diabetes
Tip		članek
Vol. in št.		Letnik 73, št. 3
Leto izdaje		2022
Obseg		str. 231-240
ISSN		0014-8229 - Farmacevtski vestnik : strokovno glasilo slovenske farmacije
Jezik		slv
Abstrakt		Optimal glycemic control and multifactorial treatment are important for type 2 diabetes control. Non-pharmacological treatment is the mainstay of antihyperglycemic treatment, but it usually merits timely escalation of pharmacological intervention. One of the barriers to pharmacological treatment with GLP-1 receptor agonists was injectable treatment due to their polypeptide composition. In 2019, the first and only oral GLP-1 receptor agonist ‐ semaglutide, was introduced to clinical use. Due to structural modifications and technological processing of the tablet, the molecule is resistant to degradation in the acidic gastric envi- ronment and has a comparable effect as in the form of injectable treatment. Oral semaglutide was effective in improving glycemic control and redu- cing body weight, and proven for its cardiovascular safety. The present article describes the mechanism of action of GLP-1 receptor agonists, the development of oral semaglutide, dosing instructions and data from studies of its efficacy and safety.
Proste vsebinske oznake		agonisti receptorjev GLP-1 antidiabetično zdravljenje peroralni semaglutid antihyperglycaemic treatment GLP-1 receptor agonists oral semaglutide